[1] Taylor LH, Hampson K, Fahrion A, et al. Difficulties in estimating the human burden of canine rabies. Acta Trop, 2017; 165, 133−40. doi:  10.1016/j.actatropica.2015.12.007
[2] Lafon M. Rabies virus receptors. J NeuroVirol, 2005; 11, 82−7. doi:  10.1080/13550280590900427
[3] Chinese Center for Disease Control and Prevention. Technical guideline for human rabies prevention and control (2016). Chin J Viral Dis, 2016; 6, 161−88. (In Chinese
[4] World Health Organization. Rabies vaccines: WHO position paper, April 2018 - Recommendations. Vaccine, 2018; 36, 5500−3. doi:  10.1016/j.vaccine.2018.06.061
[5] Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm, 2016; 7, 27−31. doi:  10.4103/0976-0105.177703
[6] Khawplod P, Jaijaroensup W, Sawangvaree A, et al. One clinic visit for pre-exposure rabies vaccination (a preliminary one year study). Vaccine, 2012; 30, 2918−20. doi:  10.1016/j.vaccine.2011.12.028
[7] Bahmanyar M, Fayaz A, Nour-Salehi S, et al. Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA, 1976; 236, 2751−4. doi:  10.1001/jama.1976.03270250019017
[8] Wilde H. Editorial Commentary: Rabies postexposure vaccination: are antibody responses adequate? Clin Infect Dis, 2012; 55, 206-8.
[9] Aoki FY, Rubin ME, Friesen AD, et al. Intravenous human rabies immunoglobulin for post-exposure prophylaxis: serum rabies neutralizing antibody concentrations and side-effects. J Biol Stand, 1989; 17, 91−104. doi:  10.1016/0092-1157(89)90032-2
[10] Bernard MC, Boudet F, Pineda-Peña AC, et al. Inhibitory effect of concomitantly administered rabies immunoglobulins on the immunogenicity of commercial and candidate human rabies vaccines in hamsters. Sci Rep, 2022; 12, 6570. doi:  10.1038/s41598-022-10281-1
[11] Rupprecht CE, Briggs D, Brown CM, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine, 2009; 27, 7141−8. doi:  10.1016/j.vaccine.2009.09.029
[12] Wasi C, Chaiprasithikul P, Auewarakul P, et al. The abbreviated 2-1-1 schedule of purified chick embryo cell rabies vaccination for rabies postexposure treatment. Southeast Asian J Trop Med Public Health, 1993; 24, 461−6.
[13] Aoki FY, Rubin ME, Fast MV. Rabies neutralizing antibody in serum of children compared to adults following post-exposure prophylaxis. Biologicals, 1992; 20, 283−7. doi:  10.1016/S1045-1056(05)80048-X
[14] Sudarshan M K. Assessing burden of rabies in India: WHO sponsored national multicentric rabies survey, 2003. Ind J Comm Med, 2005; 6, 100.
[15] Sudarshan MK, Madhusudana SN, Mahendra BJ, et al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis, 2007; 11, 29−35. doi:  10.1016/j.ijid.2005.10.007
[16] Krebs JW, Long-Marin SC, Childs JE. Causes, costs, and estimates of rabies postexposure prophylaxis treatments in the United States. J Public Health Manag Pract, 1998; 4, 56−62. doi:  10.1097/00124784-199809000-00009